WO2024231886 - COMBINATION VACCINE
National phase entry is expected:
Publication Number
WO/2024/231886
Publication Date
14.11.2024
International Application No.
PCT/IB2024/054549
International Filing Date
10.05.2024
Title **
[English]
COMBINATION VACCINE
[French]
VACCIN COMBINÉ
Applicants **
SEQIRUS INC.
475 Green Oaks Parkway
Holly Springs, North Carolina 27540, US
Inventors
CHANG, Cheng
c/o Seqirus Inc.
475 Green Oaks Parkway
Holly Springs, North Carolina 27540, US
CHEUNG, Michael
c/o Seqirus Inc.
475 Green Oaks Parkway
Holly Springs, North Carolina 27540, US
Priority Data
63/501,222
10.05.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 4408 | |
| EPO | Filing, Examination | 48811 | |
| Japan | Filing | 533 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 24955 |
Total: 79282 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to compositions comprising multiple antigens of interest for use in vaccine formulations. The compositions comprise (a) a polynucleotide (such as an RNA) comprising a nucleotide sequence encoding an antigen and (b) an antigen polypeptide. The compositions can be used in inducing an immune response in a subject and/or in the treatment or prevention of a disease, such as a respiratory viral infection.[French]
La présente invention concerne des compositions comprenant de multiples antigènes d'intérêt, destinées à être utilisées dans des formulations vaccinales. Les compositions comprennent (a) un polynucléotide (tel qu'un ARN) comprenant une séquence nucléotidique codant pour un antigène et (b) un polypeptide antigénique. Les compositions peuvent être utilisées pour induire une réponse immunitaire chez un sujet et/ou dans le traitement ou la prévention d'une maladie, telle qu'une infection virale respiratoire.